Morphologic Correlations with Homologous Recombination Deficiency in BRCA1/2-Mutated and Non-BRCA-Mutated High-Grade Serous Carcinomas

被引：0
|
作者：
Chapagain, Udita [1 ]
Sun, Lulu [2 ]
机构：
[1] Washington Univ St Louis, St Louis, MO USA
[2] Washington Univ, Sch Med, St Louis, MO USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
895
引用
收藏
页码：S1121 / S1122
页数：2
相关论文
共 50 条
  • [1] MicroRNA profiling to identify novel determinants of platinum resistance in BRCA1/2-mutated high-grade serous ovarian cancer
    Meghani, Khyati
    Gogola, Ewa
    Rottenberg, Sven
    Jonkers, Jos
    Matulonis, Ursula
    Swisher, Elizabeth
    Konstantinopoulos, Panagiotis
    Chowdhury, Dipanjan
    CANCER RESEARCH, 2017, 77
  • [2] Secondary BRCA1/2 mutations are associated with platinum resistance in BRCA1/2-mutated ovarian carcinomas
    Norguist, B.
    Taniguchi, T.
    Wurz, K.
    Karlan, B.
    Villegas, E.
    Sakai, W.
    Swisher, E.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 594 - 594
  • [3] GENOMICS OF BRCA1/2-MUTATED BREAST CANCERS
    Jonkers, J.
    CELLULAR ONCOLOGY, 2010, 32 (03) : 162 - 162
  • [4] Secondary BRCA1/2 mutations are associated with platinum resistance in a large series of BRCA1/2-mutated ovarian carcinomas
    Norquist, B.
    Sakai, W.
    Wurz, K.
    Karlan, B.
    Taniguchi, T.
    Swisher, E.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S4 - S4
  • [5] Molecular profiling comparison of BRCA1/2-mutated and BRCA1/2 non-mutated triple-negative breast cancer (TNBC)
    Arguello, D.
    Abbott, B.
    Reddy, S.
    Gatalica, Z.
    Obeid, E.
    Goldstein, L.
    CANCER RESEARCH, 2016, 76
  • [6] Responses to carboplatin in BRCA1/2-mutated breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (07): : E337 - E337
  • [7] PD-1, PD-L1 in BRCA1/2-mutated and non-mutated epithelial ovarian carcinomas (EOCs).
    Sachdev, Jasgit C.
    Arguello, David
    Abbott, Brian L.
    Reddy, Sandeep K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] BRCA1/2 reversion mutations as a mechanism of acquired drug resistance in BRCA1/2-mutated cancers
    Taniguchi, Toshiyasu
    CANCER SCIENCE, 2023, 114 : 260 - 260
  • [9] Profiling DNA damage repair and immunophenotypes in BRCA1/2 mutated high-grade serous ovarian cancers.
    Farkkila, Anniina
    Kochupurakkal, Bose
    Howitt, Brooke E.
    Strickland, Kyle C.
    Chowdhury, Dipanjan
    Shapiro, Geoffrey
    Gjini, Evisa
    Rodig, Scott J.
    Matulonis, Ursula A.
    Konstantinopoulos, Panagiotis
    D'Andrea, Alan D.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 39 - 39
  • [10] The Role of BRCA1/2-Mutated Tumor Microenvironment in Breast Cancer
    Miklikova, Svetlana
    Trnkova, Lenka
    Plava, Jana
    Bohac, Martin
    Kuniakova, Marcela
    Cihova, Marina
    CANCERS, 2021, 13 (03) : 1 - 17
12345